Last mentioned: Mar 8, 2026
Industry Consensus
Scientific American and other major outlets report a definitive decline in global animal experiment volumes.
Current Status
Regulatory bodies and industry leaders report a significant decline in animal-based IND applications.
Major CRO Pivot
Leading Contract Research Organizations announce multi-million dollar investments in digital twin and OOC labs.
Industry Pivot
Major pharma firms like AstraZeneca and Sanofi increase investment in human-on-a-chip technologies.
FDA Guidance on NAMs
The FDA issues initial framework for the submission of data derived from microphysiological systems.
FDA Modernization Act 2.0
President Biden signs legislation ending the mandate for animal testing for new drug applications.
FDA Modernization Act 2.0
President Biden signs legislation ending the animal testing mandate.
FD&C Act Passed
Federal Food, Drug, and Cosmetic Act mandates animal testing for all new drugs.
The pharmaceutical industry is undergoing a paradigm shift as regulatory changes and technological breakthroughs reduce reliance on animal models. With the FDA Modernization Act 2.0 paving the way, human-on-a-chip and AI-driven simulations are emerging as more predictive alternatives for drug safety and efficacy.
The long-standing paradigm of animal experimentation is facing an unprecedented decline as regulatory frameworks and advanced biotechnologies converge. Following the landmark FDA Modernization Act 2.0, the industry is pivoting toward 'New Approach Methodologies' that promise higher human predictive value and lower development costs.
The pharmaceutical industry is undergoing a historic shift as the FDA Modernization Act 2.0 ends the decades-long mandate for animal testing. This transition toward New Approach Methodologies (NAMs) like organ-on-a-chip and AI modeling is redefining the legal and regulatory requirements for drug safety validation.